This inventor holds 30 USPTO granted patents and 3 EPO patents, primarily in Laser Technology. Top assignees: Mitsubishi Denki Kabushiki Kaisha, Astellas Pharma Gmbh, Mitsubishi Denki K.k.. Active years: 1977-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Amagasaki, JA (1977)
- Kobe, JP (1985)
- Amagasaki, JP (1981 - 1993)
- Aichi, JP (1994)
- Nagoya, JP (1996)
- Hyogo, JP (1990 - 2000)
- Tokyo, JP (2005 - 2018)
Company Filing History:
23 out of 21,351 
3 out of 424 
2 out of 488 
Years Active: 1977-2025
Areas of Expertise:
Title: Shigenori Yagi: A Pioneer in Bispecific Antibody Innovation
Introduction
Shigenori Yagi, based in Hyogo, Japan, is an accomplished inventor and researcher with a remarkable portfolio of 30 patents. His groundbreaking work focuses on the development of bispecific antibodies, which hold significant promise in the treatment of various cancers and other medical conditions.
Latest Patents
Yagi's recent innovations include the anti-CLDN4/anti-CD137 bispecific antibody, designed for cancer treatment. This innovative antibody binds to CLDN4 and CD137, inducing an agonistic response for CD137. It promotes interferon γ production by T cells and demonstrates cytotoxic activity against cancer cells that express CLDN4 on their surfaces. Notably, this bispecific antibody has shown safe administration in non-human primates, making it a prospective candidate for human cancer treatment.
Another significant patent from Yagi is the anti-human Tie2 antibody. This antibody is intended for the prevention or treatment of diabetic macular edema, diabetic retinopathy, and critical limb ischemia by activating human Tie2. The antibody consists of four heavy and light chain variable regions, creating multiple antigen-binding sites to effectively target the conditions it aims to treat.
Career Highlights
Shigenori Yagi's career features prestigious affiliations with companies such as Mitsubishi Electric Corporation and Astellas Pharma GmbH. His work has influenced advancements in biotechnology and therapeutic interventions, underlining his role as a key player in the field of medical innovations.
Collaborations
Throughout his career, Yagi has collaborated with notable peers, including Masaki Kuzumoto and Youichiro Tabata. These collaborations have fostered an environment of innovative research and development, propelling advancements in antibody therapies.
Conclusion
Shigenori Yagi's contributions to the field of bispecific antibodies underline his status as a leading inventor in medical innovation. With a rich portfolio of patents and collaborative efforts with industry professionals, Yagi continues to pave the way for novel therapeutic solutions that address critical healthcare challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile